In conclusion, these findings suggest that the combination treatment of Doxorubicin, E2 and TNFα may be involved in decreasing the expression and activity of ESR1, potentially enhancing the chemotherapy efficacy in ER positive breast cancers. The gene discussed is TNF; the disease is breast carcinoma.